ZA201202793B - Humanized antibodies against human il-22ra - Google Patents

Humanized antibodies against human il-22ra

Info

Publication number
ZA201202793B
ZA201202793B ZA2012/02793A ZA201202793A ZA201202793B ZA 201202793 B ZA201202793 B ZA 201202793B ZA 2012/02793 A ZA2012/02793 A ZA 2012/02793A ZA 201202793 A ZA201202793 A ZA 201202793A ZA 201202793 B ZA201202793 B ZA 201202793B
Authority
ZA
South Africa
Prior art keywords
antibodies against
humanized antibodies
against human
human
humanized
Prior art date
Application number
ZA2012/02793A
Other languages
English (en)
Inventor
Roland Beckmann
Caroline Johnson-Leger
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201202793(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of ZA201202793B publication Critical patent/ZA201202793B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA2012/02793A 2009-11-19 2012-04-17 Humanized antibodies against human il-22ra ZA201202793B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
ZA201202793B true ZA201202793B (en) 2013-06-26

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/02793A ZA201202793B (en) 2009-11-19 2012-04-17 Humanized antibodies against human il-22ra

Country Status (20)

Country Link
US (1) US8545844B2 (cg-RX-API-DMAC7.html)
EP (1) EP2512511B1 (cg-RX-API-DMAC7.html)
JP (1) JP5818804B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120098783A (cg-RX-API-DMAC7.html)
CN (1) CN102665759B (cg-RX-API-DMAC7.html)
AU (1) AU2010321047B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012012003A2 (cg-RX-API-DMAC7.html)
CA (1) CA2778864C (cg-RX-API-DMAC7.html)
EA (1) EA021356B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011980A (cg-RX-API-DMAC7.html)
ES (1) ES2531996T3 (cg-RX-API-DMAC7.html)
IL (1) IL219740A0 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03362A (cg-RX-API-DMAC7.html)
MX (1) MX2012005791A (cg-RX-API-DMAC7.html)
NZ (1) NZ599438A (cg-RX-API-DMAC7.html)
PE (1) PE20121560A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500924A1 (cg-RX-API-DMAC7.html)
UA (1) UA105405C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011061119A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202793B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
AU2015253042A1 (en) * 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) * 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
CN109153709B (zh) * 2016-03-18 2022-05-27 舒泰神（北京）生物制药股份有限公司 神经生长因子突变体
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CN111032083B (zh) * 2017-05-24 2024-01-12 财团法人生物技术开发中心 抗globo h的人源化抗体及其在癌症治疗中的用途
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
JP2025520166A (ja) * 2022-06-03 2025-07-01 レオ ファーマ アクティーゼルスカブ Ｉｌ－２２ｒ抗体の液体製剤
EP4704974A1 (en) 2023-03-08 2026-03-11 LEO Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU2005299809B2 (en) * 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2006100582A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
BRPI0619118A2 (pt) * 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina

Also Published As

Publication number Publication date
ECSP12011980A (es) 2012-07-31
CN102665759B (zh) 2015-09-30
EA021356B1 (ru) 2015-05-29
US20120230990A1 (en) 2012-09-13
CN102665759A (zh) 2012-09-12
IN2012DN03362A (cg-RX-API-DMAC7.html) 2015-10-23
EP2512511B1 (en) 2015-01-07
IL219740A0 (en) 2012-07-31
EA201290360A1 (ru) 2012-11-30
PH12012500924A1 (en) 2012-11-26
CA2778864C (en) 2017-06-27
MX2012005791A (es) 2012-07-03
EP2512511A1 (en) 2012-10-24
AU2010321047B2 (en) 2016-06-09
UA105405C2 (ru) 2014-05-12
ES2531996T3 (es) 2015-03-23
KR20120098783A (ko) 2012-09-05
US8545844B2 (en) 2013-10-01
JP5818804B2 (ja) 2015-11-18
AU2010321047A1 (en) 2012-05-24
BR112012012003A2 (pt) 2016-11-29
NZ599438A (en) 2013-12-20
JP2013511267A (ja) 2013-04-04
CA2778864A1 (en) 2011-05-26
PE20121560A1 (es) 2012-12-05
WO2011061119A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
IL217919A0 (en) Humanized anti-cdcp1 antibodies
ZA201202793B (en) Humanized antibodies against human il-22ra
IL207217A0 (en) Humanized anti-c5ar antibodies
IL220404A (en) Antiseptic antibodies
PL2949666T3 (pl) Ludzkie przeciwciała przeciwko alfa-synukleinie
ZA201107529B (en) Humanized axl antibodies
IL218724A0 (en) Endoglin antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
ZA201207484B (en) Humanized anti-egfl7 antibodies and methods using same
IL215314A0 (en) Humanized antibodies against light and uses thereof
ZA201106480B (en) Humanized anti-cd19 antibody formulations
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
ZA201202227B (en) Monoclonal antibodies
IL208979A0 (en) Humanized antibodies against human interferon-alpha
GB0920324D0 (en) Antibodies
GB0905972D0 (en) Antibodies against IL-17BR
IL212795A0 (en) Fully human antibodies against n-cadherin
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB2473934A8 (en) Antibody
GB0902916D0 (en) Antibody therapy
EP2484694A4 (en) MONOCLONAL ANTIBODY AGAINST HUMAN H1G1 POLYPEPTIDE
HRP20190159T1 (hr) Antitijela humanog anti-alfa-sinukleina
IL226635B (en) Human anti-sod1 antibodies